Loading...
Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
Immune checkpoint inhibitors targeting PD-1 and PD-L1 have demonstrated anti-tumor activity in several advanced solid malignancies. In previously treated metastatic castration resistant prostate cancer (mCRPC), a small subset of patients have a therapeutic response to checkpoint inhibition. Those wh...
Na minha lista:
| Udgivet i: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7450451/ https://ncbi.nlm.nih.gov/pubmed/32922519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920936084 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|